In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 2, 2000, Pages 111-116

  Schröder, Jan K ^a   Kasimir Bauer, Sabine ^a   Seeber, Siegfried ^a   Scheulen, Max E ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Acute myeloid leukemia; Idarubicinol; MDR modifiers; Multidrug resistance

Indexed keywords

ARABINOSIDE; CYTOSINE DERIVATIVE; DAUNORUBICINOL; DEXNIGULDIPINE; GLYCOPROTEIN; IDARUBICINOL; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033968882     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050019     Document Type: Article

References (29)

1. Ames MM, Spreafico F (1992) Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 6 [Suppl 1]: 70-75
2. Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39:2070-2076
3. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273
4. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainer K, Schluger A, Penenberg D, Raymond V, ÓReilly R, Jhanwar S, Young C, Clarkson B (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674
5. Carella AM, Berman E, Maraone MP, Ganzina F (1990) Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 75:159-169
6. Cersosimo RJ (1992) Idarubicin: an anthracycline antineoplastic agent. Clin Pharmacol 11:152-167
7. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10 073-10 080
8. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819
9. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
10. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
11. Dodion P, Sanders C, Rombaut W, Mattelaer MA, Rozencweig M, Stryckmans P, Kenis Y (1987) Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol 23:1909-1914
12. Doyle A, Ross D, Fojo A, Kaufmann S, Lee E, Sridhara R, Schiffer C (1993) Expression of a 95 kDa membrane protein is associated with low daunorubicin retention in leukemic blast cells. Proc Am Soc Clin Oncol 12:302
13. Flasshove M, Scheulen ME, Meusers P, Höffken K, Skorzec M, Käding J, Schoch C, Brittinger G, Seeber S (1992) Phase II study of cytosine arabinoside and idarubicin (AIDA) in acute myelogenous leukemia including cellular and intranuclear pharmacokinetics of idarubicin. Pro Am Soc Clin Oncol 11:267
14. Gessner T, Vaughan LA, Beehler BC, Bartels CJ, Baker RM (1990) Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res 50:3921-3927
15. Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30:51-57
16. Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR (1989) Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 49:3209-3214
17. Müller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S (1994) Improved flow-cytometric detection of low P-glycoprotein expression in leukemic blasts by histogram subtraction analysis. Cytometry 15:64-72
18. Nair S, Singh SV, Samy TS, Krishan A (1990) Anthracycline resistance in murine leukemic P388 cells. Biochem Pharmacol 39:723-728
19. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32:103-108
20. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 50:6525-6528
21. Roovers DJ, Vliet M van, Bloem AC, Lokhorst HM (1999) Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 23:539-548
22. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, Vries EGE de, Valk P van der, Meijer CJLM, Pinedo HM (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475-1479
23. Schneider E, Hsiang Y-H, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183
24. Schott B, Robert J (1989) Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 38:4069-4074
25. Schröder J, Esteban M, Müller MR, Kasimir-Bauer S, Bamberger U, Heckel A, Seeber S, Scheulen ME (1996a) Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukaemia ex vivo. J Cancer Res Clin Oncol 122:307-312
26. Schröder JK, Kirch C, Flasshove M, Kaiweit H, Seidelmann M, Hilger R, Seeber S, Schütte J (1996b) Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10:1919-1924
27. Speth PAJ, Loo FA van de, Linssen PCM, Wessels HMC, Haanen C (1986) Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 40:643-649
28. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111
29. Wiernik PH, Banks PLC, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319